Author: Vikas Kumar
17 November 2023
Key Highlights of the Report:
According to a new report by Univdatos Market Insights, the Phosphodiesterase (PDE) Inhibitors Market, is expected to reach USD 4.58 Billion in 2030 by growing at a CAGR of 6.1%. Phosphodiesterase (PDE) Inhibitors are being used in healthcare organizations in various domains of cardiovascular, pulmonary, and urinary diseases. Phosphodiesterase (PDE) Inhibitors have a major application in treating erectile dysfunction. They act to block the enzyme phosphodiesterase, thus preventing the breakdown of important second messengers- cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP). Several factors are responsible for leading this market, prominently the rise in cases of chronic diseases, the rise in geriatric population, increased sedentary lifestyle, pharmaceutical investments, and a higher rate of obesity cases. The Consensus of Taiwan Society of Cardiology in May 2023 reported a prevalence of around 1-2% of heart failure in adults. The Centre for Disease Control and Prevention of the U.S. estimated that approximately 0.8 million people in the U.S. suffer from heart attack every year in May 2023.
Access Sample PDF Here- https://univdatos.com/get-a-free-sample-form-php/?product_id=47356
The report suggests that the Rise in demand for Phosphodiesterase (PDE) 5 Inhibitors is one of the major factors driving the growth of phosphodiesterase (PDE) inhibitors in the market. PDE 5 inhibitors find most use in cases of pulmonary hypertension and erectile dysfunction. They initiate vasodilation in the lung and penis by blocking the breakdown of cyclic guanosine monophosphate (cGMP). Four PDE5 inhibitors are FDA approved- sildenafil, vardenafil, tadalafil, and a recently approved drug avanafil among which sildenafil (Viagra, Pfizer), vardenafil (Levitra and Staxyn, Bayer/GlaxoSmithKline), tadalafil (Cialis, Eli Lilly), and avanafil (Stendra, Vivus) are commercially available in the U.S. PDE 5 inhibitors are safe to use and provide a better quality of life to patients. For instance, a study appeared in the Journal of Sexual Medicine in 2023 which indicates that the men exposed to PDE-5 had a 39% lower risk of dying due to cardiovascular-related diseases.
Apart from this, growing investment by governments in spreading awareness about chronic pulmonary and cardiovascular diseases will also have a positive impact on the phosphodiesterase (PDE) inhibitors market growth during the forecast period. Another prevalence seen in the phosphodiesterase (PDE) inhibitors market is collaborations between pharmaceutical organizations to promote the production of innovative PDE-5 inhibitors and to spread awareness about such chronic diseases. Reportedly, Dr. Reddy and Sunil Gavaskar collaborated in August 2023 for the “TensionMatLo” campaign to raise awareness about blood pressure control, for individuals who are currently suffering from hypertension and also for those who are at risk of acquiring this disease. Also, Lupin signed memorandum of understanding with the Government of Maharashtra, India to fight against cardiovascular diseases in June 2023.
PDE 5 Inhibitors Leading the Pharmaceutical Industry
Phosphodiesterase (PDE) inhibitors are currently leading the pharmaceutical industry due to their engagement in treating life-threatening cardiovascular and pulmonary diseases. Here are some key points to understand why phosphodiesterase (PDE) inhibitors are gaining momentum in the pharmaceutical market:
Effective FDA-approved Drugs: Several PDE 5 inhibitors are being approved by FDA for commercial sale and consumption. These drugs are efficient in action and safer to use which is the propelling factor for them in the market.
Patient Survival and Quality of Life: Because they are often more precisely directed at patient care, phosphodiesterase (PDE) inhibitors may offer improved survival rates and better quality of life for patients.
Conclusion
The global phosphodiesterase (PDE) inhibitors market is a rapidly growing field, with advancements in health care and treatments leading to improved outcomes for patients. Phosphodiesterase (PDE) Inhibitors are a kind of drug type that is most frequently used in healthcare facilities. The global phosphodiesterase (PDE) inhibitors market is expected to continue to grow in the coming years, as new drugs are continuously being designed to improve patient outcomes. As a result, there is a growing demand for phosphodiesterase (PDE) inhibitors all over the world. Overall, the global phosphodiesterase (PDE) inhibitors market represents a significant opportunity for companies and professionals in the field of pharmaceuticals. With continued research and development, it is likely that even more effective and safer options for latex gloves will become available in the future, leading to improved outcomes for patients and healthcare professionals.
Key Offerings of the Report
Market Size, Trends, & Forecast by Revenue | 2023−2030
Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
Market Segmentation – A detailed analysis by Drug Type, Route of Administration, Application, Region
Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Get a call back
